UA93981C2 - Вирус, который вызывает заболевание дыхательных путей у чувствительных k этому млекопитающих - Google Patents

Вирус, который вызывает заболевание дыхательных путей у чувствительных k этому млекопитающих

Info

Publication number
UA93981C2
UA93981C2 UA2003087814A UA2003087814A UA93981C2 UA 93981 C2 UA93981 C2 UA 93981C2 UA 2003087814 A UA2003087814 A UA 2003087814A UA 2003087814 A UA2003087814 A UA 2003087814A UA 93981 C2 UA93981 C2 UA 93981C2
Authority
UA
Ukraine
Prior art keywords
respiratory tract
virus
virus causing
causing respiratory
tract illness
Prior art date
Application number
UA2003087814A
Other languages
English (en)
Ukrainian (uk)
Inventor
Йонг Ян Корнелиус Де
Рональдус Адрианус Мария Фушье
Ден Хоген Бернадетта Герарда Ван
Альбертус Доминикус Марселлинус Эрасмус Остерхаус
Ян Грун
Original Assignee
Вироновативе Б.B.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26076820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA93981(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Вироновативе Б.B. filed Critical Вироновативе Б.B.
Publication of UA93981C2 publication Critical patent/UA93981C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18341—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

Изобретение относится к изолированному, характерному для млекопитающих вирусу (MPV), который содержит одну антисмысловую РНК, относится к семейству Paramyxoviridae, подсемейства Pneumovirinae, идентифицируется как филогенетически соответствующего рода Metapneumovirus и представляет собой изолят, депонированный как І-2614 в CNCM, Institute Pasteur, Paris. Изобретение также относится к применению указанного вируса для получения фармацевтической композиции и способам лечения и диагностики заболеваний дыхательных путей, которые вызываются указанным вирусом.
UA2003087814A 2001-01-19 2002-01-18 Вирус, который вызывает заболевание дыхательных путей у чувствительных k этому млекопитающих UA93981C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP01200213 2001-01-19
EP01203985 2001-10-18
PCT/NL2002/000040 WO2002057302A2 (en) 2001-01-19 2002-01-18 A virus causing respiratory tract illness in susceptible mammals
US46681104A 2004-03-04 2004-03-04
US14/553,957 US9334543B2 (en) 2001-01-19 2014-11-25 Virus causing respiratory tract illness in susceptible mammals

Publications (1)

Publication Number Publication Date
UA93981C2 true UA93981C2 (ru) 2011-03-25

Family

ID=26076820

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2003087814A UA93981C2 (ru) 2001-01-19 2002-01-18 Вирус, который вызывает заболевание дыхательных путей у чувствительных k этому млекопитающих

Country Status (22)

Country Link
US (10) US8927206B2 (ru)
EP (1) EP1351981B1 (ru)
JP (3) JP5503096B2 (ru)
KR (4) KR20040002853A (ru)
CN (2) CN101921732A (ru)
AU (1) AU2002228471B2 (ru)
BR (1) BR0206591A (ru)
CA (1) CA2435180C (ru)
DK (1) DK1351981T3 (ru)
EA (1) EA006879B1 (ru)
ES (1) ES2393468T3 (ru)
HK (1) HK1068898A1 (ru)
HU (1) HUP0500244A3 (ru)
IL (1) IL157003A0 (ru)
MX (1) MXPA03006430A (ru)
NO (1) NO335551B1 (ru)
NZ (2) NZ527221A (ru)
PL (1) PL213926B1 (ru)
SG (1) SG149684A1 (ru)
UA (1) UA93981C2 (ru)
WO (1) WO2002057302A2 (ru)
ZA (1) ZA200305655B (ru)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094105A1 (en) 1998-04-24 2006-05-04 University Hospitals Of Cleveland Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses
BR0206591A (pt) 2001-01-19 2005-02-01 Vironovative Bv Vìrus de rna de filamento único de sentido negativo isolado, ácido nucléico isolado ou recombinante ou seu fragmento funcional especìfico de mpv, vetor, célula hospedeira, molécula proteinácea isolada ou recombinante ou seu fragmento funcional especìfico de mpv, antìgeno, anticorpo, método para identificar um isolado viral como um mpv, isolado viral, métodos para diagnosticar virologicamente e sorologicamente uma infecção de mpv de um mamìfero, kit de diagnóstico para diagnosticar uma infecção de mpv, usos de um vìrus, de um ácido nucléico, de um vetor, de uma célula hospedeira, de uma molécula proteinácea ou seu fragmento, de um antìgeno, ou de um anticorpo, composição farmacêutica, métodos para o tratamento ou prevenção de uma infecção por mpv e de uma doença respiratória, e para obter um agente antiviral útil no tratamento de doença do trato respiratório, agente antiviral, uso de um agente viral, métodos para diagnosticar virologicamente e sorologicamente uma infecção de apv de um pássaro, uso de um teste de diagnóstico, e, método para a detecção de um anticorpo dirigido contra mpv em uma amostra
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
US20030232061A1 (en) * 2001-10-18 2003-12-18 Fouchier Ronaldus Adrianus Maria Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
KR101076102B1 (ko) 2002-02-21 2011-10-21 비로노바티브 비.브이. 메타뉴모바이러스에서 유래한 이종성 항원을 포함하는재조합 파라인플루엔자 바이러스 발현 시스템 및 백신
DE10221836A1 (de) * 2002-05-16 2003-12-04 Lohmann Animal Health Gmbh Attenuierung von Metapneumovirus
EP1534327A4 (en) * 2002-07-25 2006-08-23 Medimmune Inc METHODS OF TREATING AND PREVENTING RSV, HMPV, AND PIV USING ANTI-RSV, ANTI-MPVH, ANTI-PIV ANTIBODIES
AU2003297602A1 (en) * 2002-12-02 2004-06-23 University Of Maryland, College Park Avian pneumovirus genes, recombinant avian pneumoviruses and methods of making
WO2004057021A2 (en) * 2002-12-19 2004-07-08 UNIVERSITé LAVAL Molecular methods and compositions for detecting and quantifying respiratory viruses
US7704491B2 (en) 2003-02-28 2010-04-27 The United States Of America As Represented By The Department Of Health And Human Services Recombinant human metapneumovirus and its use
WO2004085650A1 (en) 2003-03-24 2004-10-07 The University Of Hong Kong A high-troughput diagnostic assay for the human virus causing severe acute respiratory syndrome (sars)
EP1613345B1 (en) * 2003-03-28 2010-05-26 MedImmune, LLC Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
US7354584B2 (en) * 2003-04-11 2008-04-08 Medimmune, Inc. Recombinant IL-9 antibodies
CN101410519B (zh) 2003-04-25 2013-04-24 免疫医疗有限责任公司 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法
US20050142148A1 (en) * 2003-04-25 2005-06-30 Fouchier Ronaldus A.M. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
EP1473037A1 (en) * 2003-05-02 2004-11-03 Vironovative B.V. Treatment of hPMV infections with Ribavirin
JP2007505618A (ja) * 2003-09-22 2007-03-15 インスティティ・パスツール ニパウイルスの検出方法及びヘニパウイルスに対する免疫保護を提供する方法
EP1755673B1 (en) 2004-04-12 2014-07-23 MedImmune, LLC Anti-il-9 antibody formulations and uses thereof
JP4546212B2 (ja) * 2004-10-21 2010-09-15 三菱化学メディエンス株式会社 抗原蛋白質を発現した細胞を利用する抗体測定方法
CN101548009A (zh) * 2005-03-10 2009-09-30 米迪缪尼有限公司 偏肺病毒株及其在疫苗制备和作为抗原序列表达载体的应用以及增殖该病毒的方法
US8492097B2 (en) 2006-04-24 2013-07-23 Diagnostic Hybrids, Inc. Compositions and methods for human metapneumovirus monoclonal antibodies
EP2069485A4 (en) * 2007-07-13 2011-05-25 Medimmune Llc PREPARATION OF NEGATIVE STRAND RNA VIRUSES BY ELECTROPORATION
WO2009062532A1 (en) * 2007-11-16 2009-05-22 Vironovative Bv Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains
US20090186050A1 (en) * 2007-11-16 2009-07-23 Fouchier Ron A M Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains
US20120251502A1 (en) 2008-10-24 2012-10-04 The Government of the US as Represented by the Secretary of the Dept. of health Human Ebola Virus Species and Compositions and Methods Thereof
KR101073991B1 (ko) * 2009-10-27 2011-10-21 대한민국 국내사육 닭에서 유행하는 신규한 ｂ형 조류메타뉴모바이러스 ｓｃ1509주 및 이의 용도
CN101880732B (zh) * 2010-06-29 2012-10-10 中国药品生物制品检定所 猴副流感病毒5型的rt-pcr检测方法及试剂盒
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20120237975A1 (en) 2010-10-01 2012-09-20 Jason Schrum Engineered nucleic acids and methods of use thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3682905B1 (en) 2011-10-03 2021-12-01 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
RS63244B1 (sr) 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
EA030319B1 (ru) 2012-03-20 2018-07-31 Хумабс Биомед Са Антитела, нейтрализующие rsv, mpv и pvm, и их применения
EP2833892A4 (en) 2012-04-02 2016-07-20 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS AND PEPTIDES ASSOCIATED WITH ONCOLOGY
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
EA039682B1 (ru) * 2012-06-04 2022-02-28 Хумабс Биомед Са Антитела, нейтрализующие rsv, mpv и pvm, и их применения
CN102676701B (zh) * 2012-06-11 2013-08-14 广东温氏食品集团股份有限公司 禽肺病毒通用型rt-pcr检测引物及检测方法
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
RU2015129655A (ru) 2013-01-28 2017-03-07 Эвек Инк. Антитело человека, специфичное к матапневмовирусу человека, или антиген-связывающий фрагмент указанного антитела
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CN103360472B (zh) * 2013-07-30 2015-02-25 北京市农林科学院 禽偏肺病毒抗体elisa检测试剂盒
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
CL2013002829A1 (es) 2013-10-01 2014-04-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.
AU2014329452B2 (en) 2013-10-03 2019-06-20 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP3116538A1 (en) * 2014-03-10 2017-01-18 Fondation The Ark Respiratory syncytial virus (rsv) replication inhibitors
SI3718565T1 (sl) 2015-10-22 2022-08-31 Modernatx, Inc. Cepiva za respiratorni virus
DE102016215118A1 (de) 2016-08-12 2018-02-15 Anicon Labor Gmbh Infektiöse Bronchitis (IB)-Virus Varianten und diesbezügliche Zusammensetzungen, Verwendungen und Verfahren
US10232033B2 (en) * 2016-10-31 2019-03-19 Wuhan Sanli BioTechnology Company Limited Respiratory syncytial virus vaccine
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
AU2019261570A1 (en) * 2018-04-23 2020-11-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric vectors
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
EP4351592A1 (en) 2021-06-09 2024-04-17 Universität Duisburg-Essen Method for immortalising vesicle-secreting cells
WO2023004307A1 (en) * 2021-07-19 2023-01-26 Epivax, Inc. T cell epitopes and related compositions useful in the prevention and treatment of respiratory syncytial virus infection

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1989010405A1 (en) 1988-04-22 1989-11-02 The Upjohn Company Chimeric glycoproteins containig immunogenic segments of human parainfluenza virus type 3
US5137819A (en) 1988-07-08 1992-08-11 University Of British Columbia Cellulose binding fusion proteins for immobilization and purification of polypeptides
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
GB9200117D0 (en) 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
DE69507022T2 (de) 1994-04-19 1999-06-24 Sanquin Bloedvoorziening Verfahren zur unterscheidung zwischen den varianten des menschlichen immunschwächevirus, die syncytien induzieren, und denen, die keine syncytien induzieren und primers zur verwendung in den verfahren
SE504386C2 (sv) 1994-05-30 1997-01-27 Bengt Wilhelm Toernqvist Bottenkonstruktion på ett deplacementfartygsskrov
EP1394259A3 (en) 1994-07-18 2004-04-14 Karl-Klaus Prof. Dr. Conzelmann Recombinant infectious non-segmented negative strand RNA virus
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
EP0780475B2 (en) 1995-08-09 2006-07-19 SCHWEIZ. SERUM- & IMPFINSTITUT BERN Process for the production of infectious negative-strand RNA viruses
WO1997012032A1 (en) 1995-09-27 1997-04-03 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of infectious respiratory syncytial virus from cloned nucleotide sequences
US5869036A (en) 1995-12-08 1999-02-09 St. Louis University Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine
ES2109189B1 (es) 1996-03-14 1998-05-16 Iberica Cyanamid Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas.
US6180398B1 (en) 1996-07-12 2001-01-30 Virogeneitics Corporation Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation
AU3799797A (en) 1996-07-15 1998-02-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
WO1998013501A2 (en) 1996-09-27 1998-04-02 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
US5817494A (en) 1997-05-21 1998-10-06 Incyte Pharmaceuticals, Inc. Ubiquitin conjugation proteins
US7192593B2 (en) 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
ATE501259T1 (de) 1997-05-23 2011-03-15 Us Of America As Represented By The Secretary Of The Dept Of Health And Human Services Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen
CA2295858C (en) 1997-07-11 2011-05-10 Yale University Rhabdoviruses with reengineered coats
CN1273603A (zh) 1997-09-19 2000-11-15 美国氰胺公司 减毒的呼吸道合胞病毒
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
AU6200399A (en) * 1998-10-05 2000-04-26 Akzo Nobel N.V. Avian pneumovirus vaccine and diagnostic agent
ES2288473T3 (es) 1999-05-18 2008-01-16 Dnavec Research Inc. Vector de virus deficiente en el gen de la envoltura de paramyxoviridae.
CN101392239A (zh) 1999-07-09 2009-03-25 美国政府健康及人类服务部 减毒的人-牛嵌合副流感病毒(piv)疫苗
JP3768881B2 (ja) 1999-07-29 2006-04-19 ハテブル ウムフオルマシネン アクチエンゲゼルシャフト 昇降動作をもたらす装置
FR2801607B1 (fr) 1999-11-26 2001-12-28 Merial Sas Pneumovirus du canard et vaccins correspondants
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
CN102766605A (zh) 1999-12-10 2012-11-07 由卫生与公众服务部代表的美利坚合众国政府 重组副流感病毒(piv)作为载体提供保护对抗piv及其他人类病原体引起的感染和疾病的用途
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
US6387586B1 (en) 2000-11-06 2002-05-14 Eastman Kodak Company High contrast visually adaptive radiographic film and imaging assembly for thoracic imaging
AU3652202A (en) 2000-11-28 2002-06-11 Aviron Inc Recombinant rsv virus expression systems and vaccines
US6632459B2 (en) 2000-12-11 2003-10-14 Nutricia N.V. Chlorogenic acid and an analog thereof for immune system stimulation
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
US20030232061A1 (en) 2001-10-18 2003-12-18 Fouchier Ronaldus Adrianus Maria Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
BR0206591A (pt) 2001-01-19 2005-02-01 Vironovative Bv Vìrus de rna de filamento único de sentido negativo isolado, ácido nucléico isolado ou recombinante ou seu fragmento funcional especìfico de mpv, vetor, célula hospedeira, molécula proteinácea isolada ou recombinante ou seu fragmento funcional especìfico de mpv, antìgeno, anticorpo, método para identificar um isolado viral como um mpv, isolado viral, métodos para diagnosticar virologicamente e sorologicamente uma infecção de mpv de um mamìfero, kit de diagnóstico para diagnosticar uma infecção de mpv, usos de um vìrus, de um ácido nucléico, de um vetor, de uma célula hospedeira, de uma molécula proteinácea ou seu fragmento, de um antìgeno, ou de um anticorpo, composição farmacêutica, métodos para o tratamento ou prevenção de uma infecção por mpv e de uma doença respiratória, e para obter um agente antiviral útil no tratamento de doença do trato respiratório, agente antiviral, uso de um agente viral, métodos para diagnosticar virologicamente e sorologicamente uma infecção de apv de um pássaro, uso de um teste de diagnóstico, e, método para a detecção de um anticorpo dirigido contra mpv em uma amostra
CA2467958A1 (en) 2001-11-21 2003-05-30 Brian R. Murphy Recovery of recombinant human parainfluenza virus type 1 (hpivi) from cdna
KR101076102B1 (ko) 2002-02-21 2011-10-21 비로노바티브 비.브이. 메타뉴모바이러스에서 유래한 이종성 항원을 포함하는재조합 파라인플루엔자 바이러스 발현 시스템 및 백신
DE10221836A1 (de) 2002-05-16 2003-12-04 Lohmann Animal Health Gmbh Attenuierung von Metapneumovirus
EP1534327A4 (en) 2002-07-25 2006-08-23 Medimmune Inc METHODS OF TREATING AND PREVENTING RSV, HMPV, AND PIV USING ANTI-RSV, ANTI-MPVH, ANTI-PIV ANTIBODIES
US6605283B1 (en) * 2002-11-01 2003-08-12 The United States Of America As Represented By The Secretary Of Agriculture Nucleotide sequence for the Avian Metapneumovirus (Colorado) attachment glycoprotein gene
WO2004057021A2 (en) 2002-12-19 2004-07-08 UNIVERSITé LAVAL Molecular methods and compositions for detecting and quantifying respiratory viruses
US7704491B2 (en) 2003-02-28 2010-04-27 The United States Of America As Represented By The Department Of Health And Human Services Recombinant human metapneumovirus and its use
US20060203645A1 (en) 2003-03-05 2006-09-14 Van Den Hoogen Antonius J J Apparatus and method of determining a power parameter for writing/erasing information on an optical medium
KR20060020610A (ko) 2003-04-08 2006-03-06 코로노바티브 비.브이. 사스
US20050142148A1 (en) 2003-04-25 2005-06-30 Fouchier Ronaldus A.M. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
CN101410519B (zh) 2003-04-25 2013-04-24 免疫医疗有限责任公司 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法
WO2005007078A2 (en) 2003-04-30 2005-01-27 The Boards Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (sars)
EP1533370A1 (en) 2003-11-18 2005-05-25 ViroNovative B.V. Novel atypical pneumonia-causing virus
EP1548748A1 (en) 2003-12-17 2005-06-29 Interuniversitaire Microelectronica Centrum vzw ( IMEC) A method for making probes for atomic force microscopy
WO2005080991A1 (en) 2004-02-20 2005-09-01 Erasmus Universiteit Rotterdam Method to detect antigen-specific cytolytic activity
US8318423B2 (en) 2004-07-06 2012-11-27 Focus Diagnostics, Inc. Methods and compositions for detecting rhinoviruses
NZ555118A (en) 2004-11-11 2009-09-25 Solvay Biologicals Bv Defective influenza virus particles incapable of producing functional polymerase
JP5620048B2 (ja) 2004-12-24 2014-11-05 アボツト・バイオロジカルズ・ベー・ブイＡｂｂｏｔｔ Ｂｉｏｌｏｇｉｃａｌｓ Ｂ．Ｖ． インフルエンザウイルスの救済（ｒｅｓｃｕｅ）
CN101548009A (zh) 2005-03-10 2009-09-30 米迪缪尼有限公司 偏肺病毒株及其在疫苗制备和作为抗原序列表达载体的应用以及增殖该病毒的方法
US20060228367A1 (en) 2005-04-08 2006-10-12 Medimmune, Inc. Antibodies against mammalian metapneumovirus
EP1748447B1 (en) 2005-07-28 2008-10-22 Interuniversitair Microelektronica Centrum ( Imec) Dual tip atomic force microscopy probe and method for producing such a probe
EP1925318A1 (en) 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
US20090186050A1 (en) 2007-11-16 2009-07-23 Fouchier Ron A M Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains
WO2012011868A1 (en) 2010-07-23 2012-01-26 Osterhaus A D M E Influenza vaccine
JP5923723B2 (ja) 2011-06-02 2016-05-25 パナソニックＩｐマネジメント株式会社 人物属性推定システム、人物属性推定装置、及び人物属性推定方法
WO2014045254A2 (en) 2012-09-23 2014-03-27 Erasmus University Medical Center Rotterdam Human betacoronavirus lineage c and identification of n-terminal dipeptidyl peptidase as its virus receptor
CN109402065B (zh) * 2018-08-08 2021-07-30 温氏食品集团股份有限公司 一种番鸭c亚型禽偏肺病毒弱毒株及其制备和应用

Also Published As

Publication number Publication date
EP1351981A2 (en) 2003-10-15
EA200300810A1 (ru) 2003-12-25
WO2002057302A8 (en) 2003-11-13
NZ555567A (en) 2008-07-31
US9593386B2 (en) 2017-03-14
KR101412317B1 (ko) 2014-07-24
WO2002057302A2 (en) 2002-07-25
US9803252B2 (en) 2017-10-31
KR20100034059A (ko) 2010-03-31
CN1524088A (zh) 2004-08-25
JP2014027930A (ja) 2014-02-13
US20040005544A1 (en) 2004-01-08
US10167524B2 (en) 2019-01-01
US20160244850A1 (en) 2016-08-25
US20150093746A1 (en) 2015-04-02
KR101105984B1 (ko) 2012-01-18
ZA200305655B (en) 2004-07-22
KR20110113658A (ko) 2011-10-17
NO20033272L (no) 2003-09-18
HUP0500244A3 (en) 2011-03-28
BR0206591A (pt) 2005-02-01
EA006879B1 (ru) 2006-04-28
JP5503096B2 (ja) 2014-05-28
US9376726B2 (en) 2016-06-28
SG149684A1 (en) 2009-02-27
MXPA03006430A (es) 2004-10-15
ES2393468T3 (es) 2012-12-21
US11162148B2 (en) 2021-11-02
CA2435180C (en) 2019-04-09
CA2435180A1 (en) 2002-07-25
US20170183747A1 (en) 2017-06-29
JP5813060B2 (ja) 2015-11-17
PL213926B1 (pl) 2013-05-31
US20050118195A1 (en) 2005-06-02
EP1351981B1 (en) 2012-08-08
JP2004531220A (ja) 2004-10-14
HUP0500244A2 (hu) 2005-05-30
KR20090006236A (ko) 2009-01-14
US20190119762A1 (en) 2019-04-25
WO2002057302A3 (en) 2002-12-27
NO20033272D0 (no) 2003-07-18
NO335551B1 (no) 2014-12-29
JP2011177173A (ja) 2011-09-15
PL367826A1 (en) 2005-03-07
KR20040002853A (ko) 2004-01-07
US7531342B2 (en) 2009-05-12
DK1351981T3 (da) 2012-11-26
NZ527221A (en) 2006-09-29
AU2002228471B2 (en) 2008-02-14
US20180057893A1 (en) 2018-03-01
US20140295409A1 (en) 2014-10-02
US20100143407A1 (en) 2010-06-10
US9334543B2 (en) 2016-05-10
US8722341B2 (en) 2014-05-13
CN101921732A (zh) 2010-12-22
HK1068898A1 (en) 2005-05-06
US20200140964A1 (en) 2020-05-07
IL157003A0 (en) 2004-02-08
US10519517B2 (en) 2019-12-31
KR100964413B1 (ko) 2010-06-15
US8927206B2 (en) 2015-01-06
CN1524088B (zh) 2012-11-07

Similar Documents

Publication Publication Date Title
UA93981C2 (ru) Вирус, который вызывает заболевание дыхательных путей у чувствительных k этому млекопитающих
Ye et al. The pathogenesis and treatment of theCytokine Storm'in COVID-19
WO2005063971A3 (en) Definitive endoderm
WO2004092360A3 (en) The severe acute respiratory syndrome coronavirus
WO2005108546A3 (en) Stirred-tank reactor system
WO2003084539A3 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
WO2005023083A3 (en) Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
WO2006131591A3 (en) An entacapone-containing oral dosage form
EP2204179A3 (en) Modified Vaccinia Virus Ankara for the vaccination of neonates
WO2006072348A3 (de) Alkinyl-substituierte thiophene
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
WO2002081745A3 (en) Genes involved in osteogenesis, and methods of use
WO2007070840A8 (en) Modified and pulsatile release pharmaceutical formulations of escitalopram
DE60044816D1 (de) Pulver für herstellung eines r-fe-b-verbundmagnets, korrosionsfeste r-fe-b-verbundmagnet und herstellungsverfahren dafür
WO2005023808A3 (en) Process for the preparation of renzapride and intermediates thereof
SE0401631L (sv) Ny sammansättning
WO2005096706A3 (en) Antibody to 5'-deoxy-5'-methylthioadenosine and uses thereof
WO2005002511A3 (en) Recombinant antibodies and compositions and methods for making and using the same
WO2005034857A3 (en) Methods and compositions comprising diamines as new anti-tubercular therapeutics
DE50200711D1 (de) Substanzen zur therapie von erkrankungen, die durch hochproliferierende zellen verursacht werden
WO2007048080A3 (en) Stable pharmaceutical formulations containing escitalopram and bupropion
DE60336063D1 (de) Verfahren, zusammensetzung und kit für die antigenbindung von norwalk-ähnlichen viren
EP1842548A4 (en) ANTI-HIV MEDIUM, THIS PRESENT POLYPEPTIDE, POLYPEPTIDE ENCODING GENE AND PROCESS FOR PREPARING THE ANTI-HIV MEDIUM
ATE525129T1 (de) Membrane electrodeanordnung
KR100992551B1 (ko) 폴리감마글루탐산을 포함하는 천식 또는 알레르기성 질환의예방 또는 치료용 조성물